Achelios Therapeutics Competitors and Similar CompaniesClear all
Achelios Therapeutics's competitors and similar companies include CTI BioPharma, Genoa Pharmaceuticals, Crinetics Pharmaceuticals and Sosei Heptares.
 Achelios Therapeutics Achelios Therapeutics is a biopharmaceutical development company specializing in the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules. |  CTI BioPharma CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. |  Genoa Pharmaceuticals Genoa Pharmaceuticals develops therapies for the treatment of idiopathic pulmonary fibrosis. |  Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors. | ||
Founding Date | Founding Date 2012 | Founding Date 1992 | Founding Date 2011 | Founding Date 2008 | Founding Date 1990 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Durham, US HQ | Locations Seattle, US HQ Köln, DE | Locations Seattle, US HQ | Locations San Diego, US HQ | Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB |
Employees | Employees 4 | Employees 2546% decrease | Employees 1 | Employees 43751% increase | Employees 387 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 5.1 b | Valuation ($) 697 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $53.9m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $7.7m (FY, 2025) | Revenue (est.) ¥29.6b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $3.5m (FY, 2022) | Cost of goods N/A | Cost of goods $1.1m (FY, 2025) | Cost of goods ¥7.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $50.4m (FY, 2022) | Gross profit N/A | Gross profit $6.6m (FY, 2025) | Gross profit ¥24b (FY, 2025) |
Net income | Net income N/A | Net income ($93m) (FY, 2022) | Net income N/A | Net income ($465.3m) (FY, 2025) | Net income (¥12.5b) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 3.2m | Total funding raised $ 105m | Total funding raised $ 64.2m | Total funding raised $ 41.5m | Total funding raised $ 65m |
For sources of this data, please see the company profile
View Company Profiles
CTI BioPharma
HQ
Seattle, US
Employees
25↓ 46% decrease
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
View companyGenoa Pharmaceuticals
HQ
Seattle, US
Employees
1
Genoa Pharmaceuticals develops therapies for the treatment of idiopathic pulmonary fibrosis.
View companyCrinetics Pharmaceuticals
HQ
San Diego, US
Employees
437
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors.
View company
Sosei Heptares
HQ
Tokyo, JP
Employees
387
Sosei Heptares is a biopharmaceutical company that specializes in drug development.
View company